Skip to main content

Table 1 Demographic, diagnoses, disease characteristics, and treatment at inclusion in the study, in treatment groups and controls

From: Prime-boost vaccination strategy enhances immunogenicity compared to single pneumococcal conjugate vaccination in patients receiving conventional DMARDs, to some extent in abatacept but not in rituximab-treated patients

  Rituximab Abatacept cDMARD1 Controls
N 30 23 27 28
Female gender, % 53% 83% 74% 64%
Age, median (range) years 69 (31–88)2 64 (42–78)2 68 (25–87)2 55 (18–84)
Rheumatoid arthritis, n (%) 27 (90%) 23 (100%) 14 (52%) 0
RF-positive (% of RA patients) 100% 79% 90%
Anti-CCP-positive (% of RA patients) 92% 68% 80%
Granulomatosis with polyangiitis, n (%) 3 (10%) 0 7 (26%) 0
Eosinophilic granulomatosis with polyangiitis, n (%) 0 0 3 (11%) 0
Other systemic vasculitis, n (%) 0 0 3 (11%) 0
Disease duration, median (range) years 20 (2–57) 15 (4–45) 5 (2–46)
DAS28 in RA patients, median (range) 2.7 (0.5–6.5)3 3.2 (1.5–5.5) 2.3 (1.6–4.3)
CRP, median mg/L 3.0 2.3 3.1 0.7
Total IgG, median (range) g/L 7.4 (4.0–13.9)
RTX duration, median (range) years 6.3 (0.7–10.9)
ABT duration, median (range) years 3.7 (0.7–10.2)
cDMARD duration, median (range) years 12.9 (3.3–22.4) 10.3 (4.2–20.3) 3.5 (1.4–15.3)
MTX, n (%) 16 (53%) 11 (48%) 19 (70%) 0
MTX mg/week, median 15 20 20 0
Azathioprine, n (%) 1 (3%) 0 5 (19%) 0
Azathioprine mg/day, median 150 0 100 0
Mycophenolate mofetil, n (%) 0 0 3 (11%) 0
Mycophenolate mofetil mg/day, median 0 0 1500 0
Prednisolone, n (%) 10 (33%) 10 (43%) 15 (56%) 0
Prednisolone mg/day, median (range) 5 (2.5–15) 5.6 (2.5–20) 5 (2.5–15) 0
Previous treatment with TNFα-inhibitor (%) 72.4 80.0 11.14 0
  1. 1Conventional disease-modifying antirheumatic drugs: methotrexate, azathioprine, or mycophenolate mofetil
  2. 2All treatment groups were older than controls (all p < 0.05)
  3. 3DAS28 did not differ between treatment groups
  4. 4In the cDMARD group, compared to other treatment groups, a lower proportion of patients had previously received TNFα-inhibitor treatment
\